Polygonatum Sibiricum Reduces Visceral Fat in Obese Adults
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorZhejiang Provincial Tongde Hospital
About this trial
This study is being done to find out if a traditional Chinese herb called Polygonatum sibiricum (Huangjing) can help reduce belly fat and improve metabolic health in adults with visceral obesity.
Visceral obesity means having too much fat stored deep inside the belly, around the organs. This type of fat is linked to a higher risk of diabetes, fatty liver, and heart disease.
The study will include 66 adults with visceral obesity. Participants will be randomly assigned to one of two groups:
One group will receive a Polygonatum sibiricum decoction (15 grams daily) plus standard lifestyle advice on diet and exercise.
The other group will receive the same lifestyle advice only.
The study will last for 12 weeks. Researchers will measure changes in visceral fat area, body weight, waist size, blood sugar, blood lipids, and liver fat. They will also look at gut bacteria and related markers to better understand how Polygonatum sibiricum might work.
Participation involves 4 visits to the study site over the 12-week period. All participants will receive free health assessments and dietitian guidance. The study is not a treatment but a research study to test whether this herb has potential benefits for visceral obesity.
Eligibility criteria
Qualifiers
Age 18 to 65 years, male or female;
Body mass index (BMI) ≥ 24 kg/m², or body fat percentage ≥ 25% for males or ≥ 30% for females, and visceral fat area ≥ 100 cm²;
Body weight stable within the past 3 months, with fluctuation not exceeding 5%;
Able to understand the study content, voluntarily sign the informed consent form, and willing to complete follow-up visits and required examinations as scheduled.
Disqualifiers
Secondary obesity (e.g., caused by endocrine disorders such as hypothyroidism, Cushing's syndrome, or polycystic ovary syndrome);
Previous metabolic surgery or current use of weight-loss medications;
Concomitant severe hyperglycemia or lipid metabolism disorders requiring immediate intensive treatment;
Concomitant severe cardiovascular or cerebrovascular disease, or unstable medical condition;
Trial design
Treatments tested in this trial
- Polygonatum sibiricum
- Lifestyle Intervention
Treatment groups
66 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov